<DOC>
	<DOC>NCT01140542</DOC>
	<brief_summary>This study is a proof of concept study to confirm in a standardized manner the therapeutic efficacy of roflumilast in type 2 diabetes mellitus patients.</brief_summary>
	<brief_title>Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>given written informed consent patients with diagnosis of type 2 diabetes according to American Diabetes Association (ADA) criteria and inadequately controlled on diet and exercise alone HbA1c at baseline: ≥7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and Romania) BMI between ≥26 and ≤35 kg/m2 willingness of patient to check his/her blood glucose with equipment provided by the sponsor during the treatment phase in case of hypo/hyperglycemia episodes willingness to adhere to the physician's advise to comply with diet and exercise Main patients diagnosed with type 1 diabetes or diabetes secondary to pancreatitis or resection of pancreas patients diagnosed with hemoglobinopathies, hemolytic anemia or other diseases which interfere with HbA1c measurement noneuthyroid patients or patients with a noncontrolled hypo or hyperthyroidism reported gain or loss of more than 5 percent of body weight within the last 2 months prior to V0 treatment with any diabetes medication prior to V0 treatment with any weightloss medication within 3 months prior to V0 treatment with any not allowed medication or nutrition additives clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator) clinically significant cardiac abnormalities (diagnosed clinically, or by Xray/ECG) that were not related to type 2 diabetes mellitus and that required further evaluation participation in a clinical study with study medication for weight loss or type 2 diabetes Patients were randomized after 2 weeks of the baseline period, if the following criteria were fulfilled: judged to be clinically stable tablet compliance ≥80 percent and ≤125 percent HbA1c in the range of 7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and Romania) tested at V0 by the central laboratory</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>Roflumilast</keyword>
</DOC>